Authors Posts by Joshua Rodriguez

Joshua Rodriguez

2633 POSTS 445 COMMENTS
Hey everyone, I'm Joshua Rodriguez. I'm the founder of CNA Finance as well as several other sites. If you'd like to connect with me, follow me on or Twitter! I'd love to see ya there. Also, if you're looking for top quality content for your blog, news outlet, or any other website for that matter, please reach out to me at Info@CNAFin.com! Legal Disclaimer - CNA Finance is NOT an investment advisor. All investment decisions should be well thought out and made with the help of a an investment advisor. For our full legal disclaimer, please scroll to the bottom right of this page.

0 490
CEL-SCI Corporation CVM Stock News

CEL-SCI Corporation (NYSEMKT:CVM) is having an overwhelmingly strong day in the market today and for good reason. It looks like the company is going to get its hands on a patent it was after. As a result, investor excitement ensued, leading to gains in the stock and prompting our partners at Trade Ideas to send the alert. At the moment (11:17), CVM is trading at $0.14 per share after a gain of $0.04 per share or 36.36% thus far today.





CVM Will Be Getting A New Patent

As mentioned above, CEL-SCI is having a strong day in the market today after announcing that it will be receiving a new European patent on Multikine* (injections of Leukocyte Interleukin). Multikine* is an investigational cancer immunotherapy. The patent that the company will soon receive is titled A METHOD FOR MODULATING HLA CLASS II TUMOR CELL SURFACE EXPRESSION WITH CYTOKINE MIXTURE. In a statement, Geert Kersten, CEO at CVM had the following to offer…




Our patent portfolio for Multikine consists of multiple patents issued in the United States, Europe, China and Japan. In addition to these patents that offer certain protections for Multikine, the method of manufacture for Multikine held by CEL-SCI as trade secret offers additional protections.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CVM. In particular, we’re interested in following the company through the ongoing development of Multikine*, as the treatment seems to be promising in early stages. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 486
Novartis AG (ADR) NVS Stock News

Novartis AG (ADR) (NYSE:NVS) is having a relatively rough day in the market today, spending most of the morning in the red. However, that could change due to news that was just released. The FDA has approved Rydapt. At the moment (10:32), NVS is trading at $76.72 per share after a loss of $0.34 per share (0.44%) thus far today.





FDA Approves NVS Rydapt

As mentioned above, the FDA has approved Rydapt by Novartis. The approval is for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3, in combination with chemotherapy. In a statement, Richard Pazdur, M.D., Acting Director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research and Director of the FDA’s Oncology Center of Excellence, had the following to offer about the newly approved NVS treatment:




Rydapt is the first targeted therapy to treat patients with AML, in combination with chemotherapy… The ability to detect the gene mutation with a diagnostic test means doctors can identify specific patients who may benefit from this treatment.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be watching NVS incredibly closely. In particular, we’re interested in the next step, the commercialization of Rydapt, and how the company will go about it. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 944
Radius Health Inc RDUS Stock News

Radius Health Inc (NASDAQ:RDUS) wasn’t off to the best of days early on the in the market. In fact, for the first half hour or so, the stock found itself in the red. However, an FDA approval came down the line minutes ago, exciting investors and sending the stock into the green and beyond. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:08), RDUS is trading at $40.60 per share after a gain of $1.88 per share (4.87%) thus far today.





FDA Approves RDUS TYMLOS

As mentioned above, Radius health wasn’t off to the best of days in the market today. That is, until minutes ago when an FDA approval came down the line. Minutes ago, it was announced that the United States Food and Drug Administration has made the decision to approve TYMLOS.




TYMLOS is a human parathyroid hormone related peptide [PTHrP(1-34)] analog. The treatment is indicated for postmenopausal women that are dealing with osteoporosis and are at high risk for fracture. To view the full approved label, click here.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on RDUS. In particular, now that TYMLOS is approved, we’re interested in how the company is going to go about the commercialization process. Of course, there are several companies that would likely love to partner in this venture. We’ll continue to follow the story closely and bring the news to you as it breaks!

Update (10:50): RDUS will be hosting a conference call on Monday to discuss the approval as well as 2017 EPS expectations.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 400
Neurotrope Inc NTRP Stock News

Neurotrope Inc (NASDAQ: NTRP) is having a pretty good start to the trading session today, and for good reason. The company said that it would be providing the results from key Phase 2 clinical trial incredibly soon. Of course, this led to excitement among investors, causing gains in the stock and prompting our partners at Trade Ideas to send the alert. At the moment (9:53), NTRP is trading at $15.89 per share after a gain of $0.75 per share or 4.94% thus far today.




NTRP To Announce Results Of Alzheimer’s Disease Trial

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

As mentioned above, Neurotrope is having a pretty strong start to the trading session this morning after releasing a PR stating that it would be announcing the results from a key Phase 2 clinical trial. The trial is a Phase 2 trial assessing Bryostatin-1 as a treatment for moderate to severe Alzheimer’s disease. Through the trial, the treatment was assessed in 148 patients. The trial results will be released via press release on May 1st at 8:30 am.



What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on NTRP. In particular, we’re interested in the company’s ongoing work with regard to Bryostatin-1. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 275
Ignyta Inc RXDX Stock News

Ignyta Inc (NASDAQ: RXDX) is having an incredibly strong start to the trading session this morning, and for good reason. The company announced a key program update with regard to entrectinib, a clinical stage candidate that’s nearing the NDA submission process. As a result, investor excitement ensued, leading to gains and prompting our partners at Trade Ideas to send the alert. At the moment (9:32), RXDX is trading at $9.35 per share after a gain of $0.60 per share or 6.86% thus far today.





RXDX Gains On Entrectinib Update

As mentioned above, Ignyta is having an incredibly strong start to the trading session today after announcing a comprehensive program update on entrectinib. The treatment is in the midst of a Phase 2 clinical trial known as STARTK-2. In the trial, entrectinib is being investigated as a treatment for tumors that harbor TRK, ROS1 or ALK fusions. Here are the key points that were provided through the update…




  • According to the release by RXDX, enrollment is more than 85% complete for the primary efficacy analysis to support a TRK tissue agnostic NDA submission.
  • The company also stated that more than 50 patients with ROS1 fusion-positive NSCLC have been enrolled. Interim data sampled from 32 of these patients demonstrate that 24 of them or 75% confirmed RECISTORR and 17.2 months DOR.
  • Confirmed RECIST ORR of 64%, or 7 out of 11 patients, in the ROS1 NSCLC with CNS metastases arm.
  • If clinical data continues to be positive, the company is expecting a dual NDA submission in TRK and ROS1 in 2018 with a commercial launch anticipated in 2019.

In a statement, Jonathan Lim, M.D., Chairman and CEO at RXDX had the following to offer…

Today’s update is the result of our team’s diligent efforts to advance entrectinib through the clinic for the benefit of patients with TRK and ROS1 fusion-positive cancers… We are proud to announce substantial progress towards dual entrectinib NDA submissions for both TRK and ROS1, and are excited by the opportunity to serve two distinct groups of patients with cancer.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on RXDX. In particular, we’re interested in following the ongoing work with regard to entrectinib as the treatment seems to be one that will yield strong gains in the future. Nonetheless, we’ll continue to follow the story and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 355
Sarepta Therapeutics Inc SRPT Stock News

Sarepta Therapeutics Inc (NASDAQ: SRPT) is off to an incredible start in the pre-market hours this morning, and for good reason. The company reported earnings, missing on earnings per share, but beating on revenue. Also, the company informed investors that the CEO would be stepping down. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (8:56), SRPT is trading at $36.70 per share after a gain of $1.98 per share (5.70%) thus far today.





SRPT Announces Earnings | CEO Stepping Down

As mentioned above, Sarepta Therapeutics is having an incredibly strong start to the day in the market today after reporting earnings and announcing that the CEO of the company would be stepping down. In terms of earnings, here’s what we saw:




  • Earnings Per Share – In terms of earnings per share, SRPT didn’t do all that well. During the quarter, analysts expected that the company would generate a loss of $0.36 per share. However, the loss generated was far wider, coming in at $0.60 per share.
  • Revenue – While the company did miss earnings estimates, revenue proved to be positive. During the quarter, analysts expected that SRPT would generate revenue in the amount of $13.86 million. However, the company actually generated revenue in the amount of $16.3 million.
  • Guidance – Finally, Sarepta Therapeutics said that it expects to generate $95 million throughout the year 2017, coming in right in line with analyst expectations.

On top of the earnings news, we found out that SRPT CEO Ed Kaye will be stepping down. In the filing, we learned that the plans for the CEO to step down were already in place. While Kaye will still be a director of the company, they are now in search of a new CEO.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on SRPT. In particular, we’re interested in following the CEO search and ongoing work with regard to Exondys 51. Also, many speculate that the departure of the CEO opens the door to a takeover, potentially by Sanofi (SNY). Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 539
CytRx Corporation CYTR Stock News

CytRx Corporation (NASDAQ:CYTR) is having an overwhelmingly rough morning in the pre-market hours, and for good reason. The company priced a public offering of common stock, low balling investors and leading to fear. As a result, the stock took a dive, prompting our partners at Trade Ideas to alert us to the losses. At the moment (8:36), CYTR is trading at $0.56 per share after a loss of $0.12 per share (18.21%) thus far today.





CYTR Announces Price Of Offering

As mentioned above, CytRx is having a rough start in the market today after announcing the price of a public offering. The company is planning on offering a total of approximately 30 million shares of common stock. The price per share under this offering is $0.50 and the offering is expected to close on May 2, 2017. Of course, the closing is subject to customary closing conditions.




The company said that after deducting placement agent’s fees and other expenses associated with the offering, it is expecting to generate $13.8 million. The goal is to use this money for general corporate purposes, clinical and regulatory activities, and drug discovery activities, as well as potential strategic transactions.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CYTR. In particular, we’re interested in the company’s ongoing work with regard to aldoxorubicin and how the funds gained through this offering help the company push the treatment to commercialization. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Time Inc TIME Stock News

Time Inc (NYSE: TIME) is having an overwhelmingly rough start to the trading session today, and for good reason. The company previously announced that it was looking into strategic alternatives. However, investors recently found out that the key strategic alternative is off of the table. This ultimately led to fear among investors and declines in the stock. Of course, our partners at Trade Ideas were the first to alert us to the declines. Currently (8:21), TIME is trading at $14.80 per share after a loss of $3.50 per share or 19.13% thus far today.





TIME Falls On Refusal To Sell The Company

As mentioned above, Time is taking a bit of a dive in the pre-market this morning after announcing that the strategic plan does not include the concept of selling the company. Ultimately, when the company announced that it would be looking into strategic alternatives, the hope among investors was that the company would be sold. As we know, when investors don’t quite get what they want, the stock in question tends to fall. That’s exactly what we’re seeing today.




What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on TIME. In particular, we’ll be watching for news associated with their strategic plan for growth. Also, while the company said it will not sell, investors could push it in that direction over time. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 338
BioMarin Pharmaceutical Inc. BMRN Stock News

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is having an incredible time in the market at the moment. In fact, minutes ago, the stock started spiking. The gains are ultimately the result of an FDA approval. Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (1:19), BMRN is trading at $98.31 per share after a gain of $2.24 per share or 2.33% thus far today.





FDA Approves BMRN Treatment

As mentioned above, minutes ago, BioMarin Pharmaceutical started gaining after news broke that the United States Food and Drug Administration approved the company’s new drug application. The application surrounded the now FDA approved treatment Brineura. The treatment is designed for patients dealing with Batten disease.




What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on BMRN. In particular, we’re interested in following the company’s next steps following the news of FDA approval. With this, the company is now free to move toward commercialization. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Northern Dynasty Minerals Ltd NAK Stock News

Northern Dynasty Minerals Ltd (NYSEMKT: NAK) is having a rough day in the market today. In fact, just about all basic materials companies are taking a bit of a dive. Nonetheless, I’m glad this stock came up on the Trade Ideas radar and was brought to my attention. The truth is that this is one of the most interesting Risk vs. Reward stories that I’ve seen in some time. At the end of the day, things could go very well, or very poorly, and quickly. In fact, in early May, a catalyst is coming that will largely define what we can expect to see from NAK, at least in the near term.





The Risk vs. Reward Question Surrounding NAK

As mentioned above, Northern Dynasty Minerals poses one of the most interesting Risk vs. Reward stories I’ve seen in some time. At the end of the day, the Pebble Project could prove to be massively profitable or massively expensive.

You see, the Pebble Project is in an area in Alaska known as Bristol Bay, and many argue that continued work on the project will lead to damaging effects to the environment, in particular, salmon in Bristol Bay. As a result, the EPA placed a pre-emptive veto on the project, making it impossible for NAK to apply for the permits they need in order to move forward with the project.

On the other hand, NAK believes that this fight is worth the risk. In fact, they’ve already spent more than $150 million on environmental studies to prove that they can indeed mine in Bristol Bay without posing a threat to the surrounding environment. Not to mention the hundreds of millions the company has spent on legal and other costs associated with attempting to push this project forward. So, we know the risk side.




On the reward side, if the Pebble Project were to go through, the mine would be the second largest gold mine in the world! On top of that, the mine would be the ninth largest copper mine in the world. Think of the amount of money in commodities that could be pulled out of the ground here and contributed to the Northern Dynasty Minerals balance sheet!

The Coming Catalyst

As mentioned above, while there’s a huge Risk vs. Reward argument here, there’s also a massive catalyst on the horizons that could make or break the NAK investment. At the moment, NAK is in mediation with the EPA, and that mediation is expected to come to an end before May 4th, 2017. At the end of this mediation, Northern Dynasty Minerals may have what they need to start applying for and obtaining permits. All in all, if all goes well, this would put the company on track to start mining at the Pebble Project by the year 2024.

Is The Risk Worth The Reward?

Well, that’s a question that only you can answer. What we do know here is that the potential reward here could be massive, but so too could be the losses. At the end of the day, the best thing that you can do is to do your research, get a thorough understanding of both sides of the Pebble Project, and make an educated decision once you have.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 4656
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...